Target intelligence / Profile preview

Novel protein, C2orf15-MRPL30-novel lincRNA readthrough (ENSG00000241962)

Target
ENSG00000241962
Molecular classification
Other, (Putative protein-coding or non-coding RNA readthrough product)
01

Overview

This locus represents a readthrough transcript between the adjacent *C2orf15* and *MRPL30* genes, incorporating features of both coding and non-coding regions with a presumed long intergenic non-coding RNA segment. There is no substantial protein or molecular function characterized, and it is not recognized as a relevant therapeutic target or biomarker. Such readthrough events are often identified in genome annotation projects but generally lack evidence for translation into functional proteins or roles in disease[3]. The entry "novel protein, C2orf15-MRPL30-novel lincRNA readthrough" (ENSG00000241962) refers to a readthrough transcript combining *C2orf15*, *MRPL30*, and a novel long intergenic non-coding RNA (lincRNA)[3]. This entity is catalogued as a protein-coding gene but lacks substantial experimental characterization, including protein product evidence and functional annotation. There is no evidence that this gene product is a characterized or druggable therapeutic target, such as a receptor, enzyme, transporter, or similar[3]. This entry does not correspond to a well-defined protein or therapeutic target. It likely represents a *readthrough*, which is a non-canonical transcriptional event that fuses exons from adjacent loci, often resulting in low or uncharacterized expression. There is insufficient evidence for its biological relevance as a molecular target[3]. The entry is best categorized as an uncharacterized, putative readthrough gene with unknown function. There is no literature evidence or database classification indicating a defined protein, receptor, enzyme, or drug target function for ENSG00000241962. No alias or synonym mapping it to a known therapeutic or biological target was found. If you are seeking structured information about therapeutic receptors, enzymes, or drug targets, this gene does not currently qualify based on available annotation and characterization[3].

Other names
C2orf15-MRPL30 readthroughENSG00000241962

Beyond the preview

Go deeper on Novel protein, C2orf15-MRPL30-novel lincRNA readthrough (ENSG00000241962).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel protein, C2orf15-MRPL30-novel lincRNA readthrough (ENSG00000241962).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call